Graff Jeremy R.
Graff Jeremy R.'s purchase track record
Graff Jeremy R. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/13/2023 | INAB | $2K | +52.0% | +32.8% | +15.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
IN8bio Reports Inducement Grant Under Nasdaq Rule. IN8bio disclosed an inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate governance procedure used to attract or retain key employees. The stock is currently trading near its 52-week high, with technical indicators showing recent support rejection.
Transaction History
| ALLR | ▲ Buy | Grant | 133,333 | $0 | 1/7/2026 | View on chart |
| ALLR | ▲ Buy | Option Exercise | 39,494 | — | 9/30/2025 | View on chart |
| ALLR | ▼ Sell | Tax Withholding | 14,613 | $23K | 9/30/2025 | View on chart |
| ALLR | ▲ Buy | Grant | 144,441 | $0 | 1/22/2025 | View on chart |
| ALLR | ▲ Buy | Grant | 118,483 | $250K | 9/30/2024 | View on chart |
| INAB | ▲ Buy | Grant | 2,049 | — | 12/13/2023 | View on chart |
| INAB | ▲ Buy | Open Market | 2,500 | $2K | 9/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Allarity Therapeutics expands lab capabilities and highlights DRP technology
Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.
Allarity Therapeutics expands lab capabilities and highlights DRP technology. Allarity reported progress on its Drug Response Predictor platform, noting its role in advancing the clinical development of Stenoparib. The company also announced that its in‑house laboratory now includes proteomics and cell‑line research capabilities. These updates are intended to strengthen the drug development program and support existing partnerships. The stock remains near the lower end of its 52‑week price range.